In particular, mutations in TP53, which are present in approximately 30-40% of lung cancer patients, upregulate enzymes involved in pyrimidine biosynthesis, leading to resistance to antimetabolites such as 5-FU [6–8]. Here, TP53 is linked to lung carcinoma.